A5288: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULT-OCTAVE)

You are here

Research Type: 
Research Duration: 
September 2018

The aim is to test a strategy of using resistance testing to choose the optimal ART regimen in those failing 2nd line Therapy. 

Sponsor:

  • AIDS Clinical Trials Group

Collaborator:

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Information provided by (Responsible Party):
  • AIDS Clinical Trials Group